Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.

This investor's weighing up a couple of world-class companies for his Stocks and Shares ISA after the US election sparked a sell-off.

The move intensifies the competition with Eli Lilly, which secured approval for its weight loss drug in China in July but has ...

Catalent is vulnerable to facility closures whether from natural disasters or manufacturing issues, and a warning letter from the FDA or other regulatory agency can result in manufacturing delays or ...

Novo Nordisk rose after the Danish giant launched its Wegovy weight-loss product in China. Merck reported promising trial results for a new, easier-to-administer formulation of its blockbuster cancer ...

As China rises to second place, next only to the U.S., for innovative new drugs, a new report by Clarivate – A Decade of Innovation, A Decade to Come – outlines key policy reforms and regulatory, R&D ...

With Wegovy gaining acceptance for China in Q2 2024, this opens the door for Novo Nordisk to gain a foothold in a potentially ...

Merck reported that a new formulation of Keytruda appears to deliver similar blood levels of the drug when given as a shot as ...

FRANKFURT (Reuters) - Healthcare executives and investors expect an uptick in initial public offerings and corporate ...

In a study by the Northwestern Medicine Canning Thoracic Institute in Chicago, the RNA in the SARS-CoV-2 virus was found to "trigger the development of a unique type of immune cell with anti-cancer ...

The first prescription for the drug in China will reportedly be issued at a public hospital in Shanghai this week and will ...

Patients in China will be able to purchase the blockbuster weight-loss drug Wegovy for 1,400 yuan, or about $193, just a ...